反应详情

To a solution of 400 mg 4-[(S)-5-(tert-Butyl-diphenyl-silanyloxy)-2-({5-[2-((S)-2-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}-amino)-pentanoyl]-piperazine-1-carboxylic acid butyl ester in 40 ml THF were added 0.6 ml of TBAF (1 M in THF) and the mixture stirred at RT for 12 h. It was concentrated, the residue was dissolved in DCM and washed with water (3×). The solvent was removed under reduced pressure and the residue purified by preparative HPLC (C18 reverse phase column, elution with a water/MeCN gradient with 0.1% TFA). The fractions containing the product were lyophilized to yield the pure product.

1. concentrationIt was concentrated
2. dissolutionthe residue was dissolved in DCM
3. washwashed with water (3×)
4. customThe solvent was removed under reduced pressure
5. customthe residue purified by preparative HPLC (
6. washC18 reverse phase column, elution with a water/MeCN gradient with 0.1% TFA)
7. additionThe fractions containing the product
8. customto yield the pure product